CN1013830B - Preparation process of B-ultrasonic gastrointestinal contrast agent - Google Patents
Preparation process of B-ultrasonic gastrointestinal contrast agentInfo
- Publication number
- CN1013830B CN1013830B CN 87105799 CN87105799A CN1013830B CN 1013830 B CN1013830 B CN 1013830B CN 87105799 CN87105799 CN 87105799 CN 87105799 A CN87105799 A CN 87105799A CN 1013830 B CN1013830 B CN 1013830B
- Authority
- CN
- China
- Prior art keywords
- contrast agent
- fine powder
- float
- ultrasonic
- endoconcha sepiae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000002872 contrast media Substances 0.000 title claims abstract description 17
- 230000002496 gastric effect Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 3
- 239000000843 powder Substances 0.000 claims abstract description 16
- 238000001035 drying Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 5
- 230000001954 sterilising effect Effects 0.000 claims abstract description 4
- 238000007873 sieving Methods 0.000 claims abstract description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000084 colloidal system Substances 0.000 claims description 5
- 210000001951 dura mater Anatomy 0.000 claims description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- 241001523383 Achnatherum Species 0.000 claims description 2
- 229920000832 Cutin Polymers 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 239000000470 constituent Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 239000005416 organic matter Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 abstract description 2
- 241001517299 Bulbophyllum Species 0.000 abstract 1
- 244000309464 bull Species 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 abstract 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
- 238000005516 engineering process Methods 0.000 description 4
- 208000007882 Gastritis Diseases 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 241000252983 Caecum Species 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The contrast agent prepared by the preparation process of the B-ultrasonic gastrointestinal contrast agent fills the blank of the B-ultrasonic gastrointestinal lesion examination.
The process comprises the following steps: selecting qualified Os Sepiae, washing, rinsing, drying, removing hard coat, pulverizing, sieving, sterilizing, mixing 80% of the Os Sepiae fine powder with 20% of the pulverized fine powder of Bulbophyllum splendens (Bull. ex Fr.) pers of 100 meshes, and making into capsule. Through clinical experiments of more than one thousand cases in four years, the ultrasonic coincidence rate can reach 96.2-98.6%.
Description
The contrast agent called after ST-1 gastrointestinal contrast agent that this technology makes, i.e. B ultrasonic gastrointestinal contrast agent.
This technology also is applicable to the preparation of certain treatment suppurating sore and haemostatic medicament.
Now retrieving and going up the exercise question of publishing 248～250 pages of " combination of Chinese and Western medicine magazine " fourth phase the 3rd volumes is that " the X radiodiagnosis x of theory of Chinese medical science is learned research " literary composition warp carefully contrasts with the present invention, find that this article and the present invention do not belong to same classification, that is to say, also be provided with akin research both at home and abroad with the present invention.Because the interference of factors such as gastric mucus, acoustic impedance is provided with the manufacturing process that finds suitable B ultrasonic gastrointestinal contrast agent again, so B ultrasonic still can not be checked the gastrointestinal pathological changes.
In order to address the above problem, the invention provides a kind of manufacturing process of contrast agent, prepared contrast agent has been filled up the blank that B ultrasonic is checked gastrointestinal disease.
This technology and embodiment are as follows:
Select → scrub → soak float → dry → remove dura mater → coarse crushing → in small, broken bits → dry → sieve → sterilize → encapsulated.
1. select: choose more than the long 9cm from Endoconcha Sepiae, more than the wide 5cm, more than the thick 1.5cm, color is white, complete person.
2. scrub: the Endoconcha Sepiae of picking out is washed with the soft brush of clear water.
3. soak and float: will scrub clean Endoconcha Sepiae and soak with clear water and float in the pond 2～3, and go up and push down not order with weight and float, change water every day 1～2 time, float to no saline taste and fish-stench for spending.
4. dry: as will to soak and float that good Endoconcha Sepiae is dried with daylight or with cold drying drying (being no more than 50 ℃), or Endoconcha Sepiae inside aqueous vapor be evaporated with the boulton process drying.
5. remove dura mater: the hard crisp cutin on two surfaces of Endoconcha Sepiae that drying is good, translucent epithelium by hand or mechanical means remove.
6. coarse crushing: the Endoconcha Sepiae pulverizing that will remove dura mater is coarse powder.
7. in small, broken bits: that the reprocessing of Endoconcha Sepiae coarse powder is fine powder.
8. dry: sieve for convenience, the Endoconcha Sepiae fine powder after in small, broken bits, again drying once, for cold drying (being no more than 50 ℃) makes the fine powder intensive drying.
9. sieve: dried fine powder is crossed 100 mesh sieves.
10. sterilization: the fine powder after will sieving is put in the vulcanizing tank through SO
2Gas depoisoning spreads to put under the Burdick lamp again and shone 15 minutes.The chemical constituent of Endoconcha Sepiae fine powder is: calcium carbonate is more than 80%, and colloid, organic matter are more than 10%.
11. encapsulated: the Endoconcha Sepiae fine powder with 80% is to play 20% 100 whitish eye splendid achnatherum fine powders of colloid effect, and mix homogeneously divides encapsulated.Promptly make the B ultrasonic gastrointestinal contrast agent.
Its radiography principle is as follows: produce CO in the calcium carbonate in the contrast agent He behind the gastric acid
2Bubble, drink water and be " flakes " phenomenon of swimming after 500～1000 milliliters, because can build up, be fused into rope piece or light on the colloid confrontation ulcer in the contrast agent, the cancerous protuberance mucomembranous surface cliques graph and resembles, form tangible interface, because contrast agent can make the full difference of coat of the stomach mucosa aspect acoustic impedance that causes of gastral cavity, thereby show stomach form, position, gastral cavity size, wall of stomach thickness, emptying time and gastropathy place situation; Can show gastrointestinal dysfunction; The pathological changes that shows small intestinal, caecum, each position of colon.
B ultrasonic gastrointestinal contrast agent with this process trial one-tenth, end from year June nineteen eighty-three to 1987,1323 routine cases have been done altogether, gastritis, antral gastritis, chronic line table gastritis, gastroptosis, gastric cancer and gastroenteric tumor are diagnosed, and with X line, gastroscope, pathological biopsy, operating comparison, ultrasonic coincidence rate can reach 96.2～98.6%.
Attached: one piece of document that Guiyang City Science and Technology Committee retrieves reaches the analysis report to result for retrieval.
Claims (1)
1, the manufacturing process of B ultrasonic gastrointestinal contrast agent, float by selecting, scrub, soaking, drying, coarse crushing, in small, broken bits, dry, sieve, sterilization, encapsulatedly constitute, it is characterized in that
1) soak and float: will scrub clean Endoconcha Sepiae and soak with clear water and float on 2-3 day in the pond, and go up and push down not order with weight and float, change water 1-2 every day, floats to no saline taste and fish-stench and be advisable;
2) remove dura mater: behind drying program, increase the dura mater process of removing, the hard crisp cutin on two surfaces of Endoconcha Sepiae that drying is good, translucent epithelium by hand or mechanical means remove;
3) sterilization: the fine powder after will sieving is put in the thinization jar through SO
2Gas depoisoning, irradiation 15 minutes is put Burdick lamp under at the stand again, makes the chemical constituent of Endoconcha Sepiae fine powder be: calcium carbonate is more than 80%, colloid, organic matter is more than 10%;
4) encapsulated: be with 80% Endoconcha Sepiae fine powder and 20% the 100 whitish eye splendid achnatherum fine powders that play the colloid effect, mix homogeneously divides encapsulatedly, makes the B ultrasonic gastrointestinal contrast agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 87105799 CN1013830B (en) | 1987-08-26 | 1987-08-26 | Preparation process of B-ultrasonic gastrointestinal contrast agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 87105799 CN1013830B (en) | 1987-08-26 | 1987-08-26 | Preparation process of B-ultrasonic gastrointestinal contrast agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN87105799A CN87105799A (en) | 1988-04-06 |
| CN1013830B true CN1013830B (en) | 1991-09-11 |
Family
ID=4815451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 87105799 Expired CN1013830B (en) | 1987-08-26 | 1987-08-26 | Preparation process of B-ultrasonic gastrointestinal contrast agent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1013830B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2114637C1 (en) * | 1991-09-17 | 1998-07-10 | Сонус Фармасьютикалз, Инк. | Biologically compatible contrast medium and method for producing ultrasonic images |
| MX9205298A (en) | 1991-09-17 | 1993-05-01 | Steven Carl Quay | GASEOUS ULTRASOUND CONTRASTING MEDIA AND METHOD FOR SELECTING GASES TO BE USED AS ULTRASOUND CONTRASTING MEDIA |
| US6723303B1 (en) | 1991-09-17 | 2004-04-20 | Amersham Health, As | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane |
| US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
| IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Phase shift colloids as ultrasound contrast agents |
| US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
| SG52198A1 (en) * | 1993-01-25 | 1998-09-28 | Sonus Pharma Inc | Phase shift colloids as ultrasound contrast agents |
| CN1051006C (en) * | 1994-08-31 | 2000-04-05 | 宋振才 | Quick-acting contrast medium for cholecystography and cholangiography |
| US5837221A (en) * | 1996-07-29 | 1998-11-17 | Acusphere, Inc. | Polymer-lipid microencapsulated gases for use as imaging agents |
| US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
| CN110251694B (en) * | 2019-07-15 | 2022-08-12 | 陕西中医药大学 | Gastrointestinal ultrasonic contrast agent and preparation method thereof |
-
1987
- 1987-08-26 CN CN 87105799 patent/CN1013830B/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CN87105799A (en) | 1988-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1013830B (en) | Preparation process of B-ultrasonic gastrointestinal contrast agent | |
| Yui et al. | Molecular and crystal structure of konjac glucomannan in the mannan II polymorphic form | |
| Phemister et al. | Calcium carbonate gall-stones and calcification of the gall-bladder following cystic-duct obstruction | |
| Bradner et al. | Reef development in the Middle Triassic (Ladinian and Cordevolian) of the Northern Limestone Alps Near Innsbruck Austria | |
| Allen et al. | Aragonite-cemented sandstone from outer continental shelf of Delaware Bay; submarine lithification mechanism yields product resembling beachrock | |
| Tuur et al. | Liesegang Rings in Tissue: How to Distinguish Liesegang Rings from the Giant Kidney Worm: Dioctophyma renale | |
| Schröder et al. | Adenolipoma (thyrolipoma) of the thyroid gland report of two cases and review of literature | |
| CN1319992C (en) | Prepn process and application of Chinese yam starch | |
| Fechner | Hodgkin's disease of the thymus | |
| Knutsson | On limy bile | |
| CN101675915B (en) | Preparation and application of bamboo charcoal slurry | |
| CN1342714A (en) | Process for extracting heparin sodium by integrated biologic method | |
| US4664916A (en) | Method for the preparation of a food having desalinating activity | |
| Shein et al. | Aggregate formation in salt-affected soils of the Baer mounds | |
| Geptner et al. | Hydrothermal fossilization of microorganisms at the Earth's surface in Iceland | |
| Shapiro et al. | Synchronous occurrence of parathyroid carcinoma and adenoma in an elderly woman | |
| Watanabe | Histochemical studies on mucosubstances in urinary stones | |
| CN103013340B (en) | Preparation method of bleached lac | |
| Mapp et al. | Roentgen diagnosis of Armillifer armillatus infestation (porocephalosis) in man. | |
| RU2819217C1 (en) | Method of producing enterosorbent from sunflower husks | |
| CN101112384A (en) | Preparation technics of Chinese traditional medicine mirabilite fine particles having better water absorptivity for external appliance | |
| Kochhar | Post-emplacement alkali modifications in rapidly cooled acid volcanic rocks | |
| Parker | Notes on Biliary and Intestinal Sand | |
| Van Buchem | Peptic Ulcer of the Greater Curvature of the Stomach | |
| KR100452181B1 (en) | A ocher dye manufacturing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C13 | Decision | ||
| GR02 | Examined patent application | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |